Verana Health, Guardant Health Combine Real-World Data to Accelerate Precision Oncology
Event summary
- Verana Health partners with Guardant Health to combine EHR and genomics data for precision oncology research.
- Collaboration enables validation of biomarker-treatment-outcome correlations, particularly for NMIBC and solid tumors.
- Verana Health's recent COTA merger expands its oncology data access to over 10 million patients across 30 Academic Medical Centers.
- Combined entity serves 17 of the top 20 global biopharma companies with access to over 95 million patients.
The big picture
This partnership underscores the growing importance of real-world data in precision oncology, enabling more targeted therapy development. The combination of Verana Health's curated EHR data with Guardant Health's clinicogenomic testing data creates a comprehensive dataset that could redefine how biopharmaceutical researchers approach drug development. The recent COTA merger further solidifies Verana Health's position as a key player in the real-world data space, with significant implications for the broader life sciences industry.
What we're watching
- Data Integration
- How effectively Verana Health and Guardant Health integrate their datasets to enhance clinical insights.
- Regulatory Alignment
- Whether the combined regulatory expertise will strengthen FDA collaborations and accelerate drug approvals.
- Market Expansion
- The pace at which the partnership expands into other solid tumors beyond lung, breast, and colorectal cancers.
Related topics